Author: Io Therapeutics, Inc.

RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models

August 5, 2026
Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

March 25, 2026

RXR Nuclear Receptor Agonists Promote Clearance of Alpha-Synuclein in Cellular Models